FDA's Financial Disclosure Requirements Might Extend To Comments On Citizen Petitions
Executive Summary
Encouraging disclosure of any financial relationship with affected drug companies by those commenting on citizen petitions could be one way FDA could respond to a Senate report questioning tactics by Sanofi-Aventis in seeking to delay approval of a generic version of Lovenox (enoxaparin sodium injection), the firm's low molecular weight heparin.
You may also be interested in...
Clinical Investigators' Financial Disclosures May Become Public Under FDA Draft Guidance
FDA draft guidance, which includes many concepts recommended by HHS OIG, replaces document finalized in 2001.
Physician Payments Sunshine Rule From CMS Expected By Year's End
Pharmaceutical companies will have a little more than a year to put together data to comply with CMS regulations for reporting payments made to physicians if the agency meets its current timeline for issuing the rules.
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
Agency's five criteria for determining "sameness" of generic enoxaparin to Sanofi-Aventis's low molecular weight heparin could serve as guideposts for future biosimilar approvals.